Nephron Research downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Exact Sciences downgraded to Equal Weight from Overweight at Barclays
- Exact Sciences downgraded to Market Perform from Outperform at William Blair
- Exact Sciences downgraded to Equal Weight from Overweight at Wells Fargo
- Exact Sciences downgraded to Peer Perform from Outperform at Wolfe Research